Referral
Subject: Urgent Referral for Evaluation of Severe Neonatal Thrombocytopenia
Dear Colleague,
I am referring a 2-day-old female neonate, delivered full-term via normal vaginal delivery, for urgent evaluation and management of severe thrombocytopenia identified during routine laboratory assessments. Her platelet count was notably low at 7,000/µl, raising concerns for an underlying hematological disorder.
Patient Details:
- Age: 2 days old
- Delivery: Full-term, normal vaginal delivery
- Perinatal History: No significant complications or maternal health issues reported.
Clinical Presentation: The neonate appears well on examination, with no evident abnormalities in vital signs or physical findings. There are no signs of petechiae, purpura, or mucosal bleeding observed during the initial assessment. Her abdomen is soft, non-distended, with no hepatosplenomegaly, and her skin appears normal without rashes or discoloration.
The family is understandably anxious about the baby’s condition and eager for any insights that could help in managing her care effectively. Your expertise in pediatric hematology will be invaluable in guiding the diagnostic process and treatment plan.
Thank you.
Reply
Dear Colleague,
Thank you for your referral of the 2-day-old neonate diagnosed with severe thrombocytopenia. Following a comprehensive evaluation and considering the family history of similar presentations, we have initiated targeted investigations and treatments to address and manage this condition effectively.
Patient Overview:
- Age: 2 days old
- Clinical Status: The neonate is alert and active, weighing 3.2 kg, and exhibits no dysmorphic features or signs of active bleeding. A normal chest examination was noted, and although the liver was palpable, there was no evidence of splenomegaly or lymphadenopathy.
- Family History: Notably, two siblings also presented with thrombocytopenia at birth, which strongly suggests a familial pattern.
Diagnostic Workup and Findings:
- Complete Blood Count (CBC): Repeated for the neonate and conducted for the mother, with the mother’s results returning normal.
- Infectious Screening: TORCH screening was performed to rule out congenital infections, which returned unremarkable.
- Imaging Studies: An urgent cranial ultrasound was conducted to ensure no intracranial hemorrhages were present; results were normal.
- Urinalysis: Conducted to exclude renal vein thrombosis, and findings were within normal limits.
Initial Impression:
Given the clinical presentation and family history, the working diagnosis was Neonatal Alloimmune Thrombocytopenia (NAIT). This condition is typically due to maternal antibodies against fetal platelet antigens not inherited from the mother.
Management Plan
- Platelet Transfusion: Due to the unavailability of HPA-1a-negative/HPA-5b-negative platelet concentrates, typed and matched random donor platelets were administered.
- Immunoglobulin Therapy: Intravenous immunoglobulin (IVIG) was started at a dose of 1 gm/kg once daily for three days to mitigate the immune response and aid in recovery of platelet counts.
Current Status and Follow-Up
The baby’s platelet count showed significant improvement over a period of three weeks. This recovery was closely monitored through regular follow-ups at our hematology clinic. The patient’s condition stabilized, and no bleeding complications were observed during the treatment period.
Discussion
Neonatal Alloimmune Thrombocytopenia (NAIT) is a critical hematological disorder in neonates, distinguished by severe thrombocytopenia caused by the placental transfer of maternal immunoglobulin G (IgG) antibodies. These antibodies are directed against fetal platelet antigens, which are inherited from the father and not shared by the mother, making NAIT the leading cause of severe thrombocytopenia in newborns.
Pathophysiology and Immunogenetics: NAIT primarily results from maternal sensitization to paternal antigens on the fetal platelets, particularly the human platelet antigen-1a (HPA-1a) and to a lesser extent, HPA-5b. Anti-HPA-1a is responsible for approximately 75%-80% of NAIT cases and targets the polymorphic Leu33Pro residue of the platelet membrane glycoprotein IIIa (GPIIIa). Anti-HPA-5b, implicated in about 10%-15% of cases, tends to be associated with less severe clinical outcomes.
Clinical Presentation: The clinical manifestations of NAIT can vary significantly:
- Most neonates present with petechiae, purpura, or ecchymoses, observable within hours after birth.
- Severe cases may involve bleeding into major organs, including gastrointestinal and pulmonary systems.
- Intracranial hemorrhage (ICH) is a particularly severe complication, occurring in 7% to 26% of NAIT cases, potentially leading to death or long-term neurological impairments.
Diagnosis and Differential Considerations: Distinguishing NAIT from autoimmune thrombocytopenia is crucial for appropriate management. In autoimmune thrombocytopenia, maternal autoantibodies, often arising from conditions like idiopathic thrombocytopenic purpura or systemic lupus erythematosus, target both maternal and fetal platelets. In contrast, NAIT exclusively affects fetal platelets due to alloantibodies against specific fetal antigens.
Management Strategies:
- Platelet Transfusions: Essential for managing acute bleeding risks, particularly in neonates with platelet counts below 30,000/μL or evident bleeding symptoms. The transfusion platelets should be matched or compatible with maternal antibodies to avoid destruction by existing antibodies. Ideally, maternal platelets are used after being washed and irradiated to remove antiplatelet antibodies and prevent graft-versus-host disease.
- Intravenous Immunoglobulin (IVIG): Administered as 400 mg/kg/day for 3–4 days or 1 g/kg/day for 1–3 days, IVIG helps increase platelet counts by blocking Fc receptors and modulating immune responses. However, its effect typically begins after 18 to 24 hours, and it should not be relied upon as the sole treatment modality.
Recent Advances and Recommendations: Recent guidelines emphasize the importance of early identification and treatment to prevent severe complications, especially ICH (check this article by ASH). Advances in understanding the genetic underpinnings and immune mechanisms of NAIT have improved diagnostic accuracy and treatment approaches, including the potential use of more targeted immunotherapies in the future.
In conclusion, NAIT requires a multidisciplinary approach involving neonatologists, hematologists, and potentially immunologists to ensure timely and effective treatment and to mitigate the risks associated with this potentially life-threatening condition. Ongoing research and clinical trials continue to enhance our understanding and management of this complex disorder.
Read More Articles About NAIT
Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management
How I diagnose and treat neonatal thrombocytopenia
Check the correct answers.
Question-1:
Correct Answer: A) HPA-1a (Human Platelet Antigen-1a)
Explanation: NAIT most frequently occurs when the mother forms antibodies against the HPA-1a antigen on fetal platelets, an antigen inherited from the father that the mother does not possess. This immune reaction leads to fetal and neonatal platelet destruction. The HPA-1a antigen is involved in approximately 75%-80% of NAIT cases, making it the most common trigger for this condition.
Question-2:
Correct Answer: B) Platelet transfusion compatible with maternal antibodies
Explanation: The first-line treatment for neonates with NAIT and significant bleeding involves transfusing platelets that are compatible with maternal antibodies, specifically those that do not carry the antigen which the maternal antibodies target. This approach helps ensure that the transfused platelets are not destroyed by the maternal antibodies present in the neonate’s circulation. This is critical in managing acute bleeding episodes in NAIT and differs from treatments for other forms of thrombocytopenia, where such specific compatibility may not be necessary.
References
- Kaplan C. Foetal and neonatal alloimmune thrombocytopaenia. Orphanet J Rare Dis. 2006; 1:39.
- Rodríguez Wilhelmi P, Aranguren A, Muñiz E, et al. Trombocitponenia fetal/neonatal aloinmune. Revisión a propósito de un caso. An Sist Sanit Navar. 2008; 31:281–287.
- Muñiz-Díaz E, Ginovart Galiana G. [Fetal-neonatal alloimmune thrombocytopenia] [in Spanish] An Pediatr (Barc) 2003; 58:562–567.
- Skogen B, Killie MK, Kjeldsen-Kragh J, et al. Reconsidering fetal and neonatal alloimmune thrombocytopenia with a focus on screening and prevention. Expert Rev Hematol. 2010; 3:559–566.
- Porcelijn L, Van den Akker ES, Oepkes D. Fetal thrombocytopenia. Semin Fetal Neonatal Med.2008; 13:223–230.
Leave a Reply